Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorpromazine for cannabinoid hyperemesis syndrome
ACTRN12609000573257Phase 4Not yet recruiting
- Sponsor
- Charlotte Heldreich
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Aminazin in Cannabinoid hyperemesis syndrome (CHS) (2 arms), sponsored by Charlotte Heldreich. Primary endpoint: Reduction in self-recorded episodes of vomiting. Planned start Aug 2009; status: not yet recruiting.
02
Drugs
Aminazin
03
Conditions
Cannabinoid hyperemesis syndrome (CHS)
Beyond the preview
Go deeper on ACTRN12609000573257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000573257.